Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 258Magnetic Resonance Spectroscopy 213pembrolizumab 202Carboplatin 170Cisplatin 137Biopsy 133Cyclophosphamide 130Paclitaxel 120Nivolumab 109Gemcitabine 102Bevacizumab 102Radiotherapy 81Dexamethasone 77Pemetrexed 75atezolizumab 71Fluorouracil 71fludarabine 68Doxorubicin 67Leucovorin 66Docetaxel 65Radiation 64Oxaliplatin 62Rituximab 60venetoclax 58Prednisone 57Cetuximab 54durvalumab 53Vincristine 52Etoposide 51130-nm albumin-bound paclitaxel 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × guadecitabine × 30 days × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡